

---

## ... BIBLIOGRAPHY ...

- Adams S, Melo J, Anzueto A. Effect of antibiotics on the recurrence rates of chronic obstructive pulmonary disease exacerbations. *Chest*. In press.
- Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. *Arch Intern Med* 1999;159:266-270.
- Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.
- Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. *QJM* 1995;88:61-68.
- Balter MS, Hyland RH, Low D, et al. Recommendations on management of chronic bronchitis. *Can Med Assoc J* 1994;151(suppl 10):S5-S23.
- Barber M. Methicillin-resistant staphylococci. *J Clin Pathol* 1961;14:385.
- Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. *Clin Infect Dis* 1998;26:811-838.
- Bartlett JG, Mundy LM. Community-acquired pneumonia. *N Engl J Med* 1995;333:1618-1624.
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. *J Antimicrob Chemother* 1997;40:639-651.
- Beardon DT, Rodvold KA. Penetration of macrolides into pulmonary sites of infection. *Infect Med* 1999;16:480-484A.
- Blondeau JM. A review of the comparative in vitro activities of twelve antimicrobial agents, with a focus on five new "respiratory quinolones." *J Antimicrob Chemother* 1999;43(suppl B):1-11.
- Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant *Staphylococcus aureus*. *J Infect Dis* 1991;163:1279-1285.
- Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. *Antimicrob Agents Chemother* 1997;41:1594-1597.
- Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. *N Engl J Med* 1999;341:233-239.
- Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARIS Study Steering Committee and Research Group. *Am J Respir Crit Care Med* 1997;156:1719-1724.
- Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. *Am J Respir Crit Care Med* 1996;154(4 Pt 1):959-967.
- DeAbate CA, Henry D, Beusch G, et al. Sparfloxacin vs ofloxacin in the treatment of acute exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. *Chest* 1998;114:120-130.
- DeAbate CA, McIvor RA, McElvaine P, et al. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. *J Respir Dis* 1999;20(11 suppl):S23-S29.
- DeAbate CA, Russell M, McElvaine, et al. A multicenter randomized study comparing levofloxacin and cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis. *Respir Care* 1997;42:206-213.
- Destache CJ, Dewan N, O'Donohue WJ, Campbell JC, Angelillo VA. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. *J Antimicrob Chemother* 1999;43:107-113.
- Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to Gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the US, Canada, and Latin America. *Clin Infect Dis* 1999;29:595-607.

---

... BIBLIOGRAPHY ...

- Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. *Antimicrob Agents Chemother* 1996;40:1208-1213.
- Doern GV, Brueggemann AB, Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of *Haemophilus influenzae* in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. *Antimicrob Agents Chemother* 1997;41:292-297.
- Doern GV, Jones RN, Pfaller MA, Kugler K, and the SENTRY Participants Group. *Haemophilus influenzae* and *Moraxella catarrhalis* from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). *Antimicrob Agents Chemother* 1999;43:385-389.
- Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of *Streptococcus pneumoniae* in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. *Clin Infect Dis* 1998;27:764-770.
- Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. *Am J Med* 1995;99(suppl 6B):3S-7S.
- Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. *Chest* 1998;113:1542-1548.
- Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. *Am Rev Respir Dis* 1990;142:1004-1008.
- File TM Jr, Tan JS, Plouffe JF. The role of atypical pathogens: *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila* in respiratory infection. *Infect Dis Clin North Am* 1998;12:569-592.
- Grant FM, Nicolau DP. Pharmacodynamic considerations in the selection of antibiotics for respiratory tract infections: Focus on the fluoroquinolones. *Antibiotics for Clinicians*. In press.
- Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian Ciprofloxacin Health Economic Study Group. *Chest* 1998;113:131-141.
- Hammerschlag MR. Community-acquired pneumonia due to atypical organisms in adults: Diagnosis and treatment. *Infect Dis Clin Pract* 1999;8:232-240.
- Jacobs MR. Treatment and diagnosis of infections caused by drug-resistant *Streptococcus pneumoniae*. *Clin Infect Dis* 1992;15:119-27.
- Jones RN, Barry AL, Gardiner RV, Packer RR. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective trial of isolates from 40 medical centers. *Diagn Microbiol Infect Dis* 1989;12:385-394.
- Lister PD. Multiply-resistant pneumococcus: Therapeutic problems in the management of serious infections. *Eur J Clin Microbiol Infect Dis* 1995;14(suppl 1):S18-S25.
- Lode H. Respiratory tract infections: When is antibiotic therapy indicated? *Clin Ther* 1991;13:149-156.
- Lund BC, Ernst EJ, Klepser ME. Strategies in the treatment of penicillin-resistant *Streptococcus pneumoniae*. *Am J Health Syst Pharm* 1998;55:1987-1994.
- Lundback B, Nystrom L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden; respiratory symptoms assessed in a postal survey. *Eur Respir J* 1991;4:257-266.
- Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995;152(4 Pt 1):1316-1320.
- Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. *Clin Ther* 1999;21:576-591.

---

... BIBLIOGRAPHY ...

- Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. *N Engl J Med* 1999;340:1941-1947.
- Niroumand M, Grossman RF. Airway infection. *Infect Dis Clin North Am* 1998;12:671-688.
- Oh P, McIvor A. The pharmacoeconomics of respiratory tract infections. *Clin Pulmonary Med* 1996;3:323-328.
- Owens RC Jr, Ambrose PG, Wikler M. Review of structure-toxicity relationships of fluoroquinolones. Presented at the Infectious Diseases Society of America, 37th Annual Meeting, Philadelphia, PA, November 18-21, 1999. Abstract No. 94.
- Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. *Diagn Microbiol Infect Dis* 1999;33:283-297.
- Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. *JAMA* 1995;273:957-960.
- Sanders CC, Sanders WE Jr, Thomson KS. Fluoroquinolone resistance in staphylococci: New challenges. *Eur J Clin Microbiol Infect Dis* 1995;14 (suppl 1):S6-S11.
- Schentag JJ, Birmingham MC, Paladino JA, et al. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. *Semin Respir Infect* 1997;12:278-293.
- Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *Am J Respir Crit Care Med* 1998;157(5 Pt 1):1498-1505.
- Spink WW, Ferris V. Quantitative action of penicillin inhibitor from penicillin-resistant strains of staphylococci. *Science* 1945;102:221.
- Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. *Arch Intern Med* 1999;159:2575-2580.
- Thornsberry C, Hickey ML, Diakun DR, et al. Sequential surveillance of antimicrobial resistance in the United States: *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* (1997-1998 vs. 1996-1997). Presented at: The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, September 24-27, 1998. [Abstract E-22].
- Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* in the United States in 1996-1997 respiratory season. *Diagn Microbiol Infect Dis* 1997;29:249-257.
- Viegi G, Paoletti P, Carrozzi L, et al. Prevalence rates of respiratory symptoms in Italian general population samples exposed to different levels of pollution. *Environ Health Perspect* 1991;94:95-99.
- Williams RJ, Heymann DL. Containment of antibiotic resistance. *Science* 1998;279:1153-1154.